Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The third dose of RabAvert was on Sunday the 31st, but it was missed; Case reference number US-BN-2025-001494 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV25-2179) on 02-Sep-2025 and concerns a 65-years-old male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient had a dog bite. On an unspecified date, unknown of time after dog bite, the patient received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration for unknown indication. On an unspecified date, unknown amount of time after dog bite, the patient received the second dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration The third dose was on Sunday the 31st, but it was missed (explicitly coded as 'missed dose'). At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: This case concerns a 65-year-old male patient, who received first two doses of RabAvert vaccine for an unknown indication. As reported, patient missed the third dose, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 65-year-old male patient, who received first two doses of RabAvert vaccine for an unknown indication. As reported, patient missed the third dose, which is considered as product dose omission issue. Product dose omission issue is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's relevant medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.